Edwards EVOQUE Eos MISCEND Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

February 6, 2015

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2033

Conditions
Mitral Valve Regurgitation (Degenerative or Functional)
Interventions
DEVICE

Edwards EVOQUE Eos Mitral Valve Replacement System

Replacement of the mitral valve through a transcatheter approach

Trial Locations (19)

11576

St. Francis Hospital, Roslyn

19104

The Hospital of the University of Pennsylvania, Philadelphia

22908

University of Virginia Health System, Charlottesville

30322

Emory University Hospital/Emory University Hospital Midtown, Atlanta

44195

Cleveland Clinic, Cleveland

46260

St. Vincent Heart Center, Indianapolis

60611

Northwestern University, Chicago

75093

The Heart Hospital Baylor Plano, Plano

77030

The University of Texas Health Science Center at Houston/Memorial Hermann Texas Medical Center, Houston

84107

Intermountain Medical Center, Murray

90048

Cedars-Sinai Medical Center, Los Angeles

94010

Sutter Mills-Peninsula, Burlingame

94118

Kaiser Permanente San Francisco, San Francisco

97239

Oregon Health & Science University, Portland

02215

Beth Israel Deaconess Medical Center, Boston

07960

Morristown Medical Center, Morristown

Unknown

St. Paul's Hospital, Vancouver

St. Michael's Hospital, Toronto

G1V 4G5

Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Université Laval, Québec

Sponsors
All Listed Sponsors
lead

Edwards Lifesciences

INDUSTRY